期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 60, 期 3, 页码 1177-1182出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02041-15
关键词
-
Novel tuberculosis (TB) drug regimens are urgently needed, and their development will be enabled by improved preclinical approaches that more effectively inform and ensure safe selection of clinical candidates and drug combination/regimens. An evidence-based approach for the assessment of nonclinical models supporting TB drug development has been proposed by a joint partnership between the National Institute of Allergy and Infectious Diseases (NIAID) and the Critical Path to TB Drug Regimens (CPTR) Consortium.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据